The UNM Cancer Center requests support of two clinical investigator faculty members who are major contributors to the programmatic and translational activities of the Center. We have highlighted their roles in facilitating the clinical components of the Center. Authorship of clinical trials, accrual of patients on interventional trials and leadership roles in cooperative group studies are particular areas of concentration Dr. Rabinowitz is currently an Associate Professor and Director of the University of New Mexico Cancer Center Clinic. He obtained his MD in 1984 at the University of Witwatersrand Medical School, in Johannesburg, South Africa. He completed a Residency in Internal Medicine, at Vanderbilt University in 1989, and then a fellowship in Hematology-Oncology, at Washington University in St. Louis in 1992. He joined the faculty of the UNM Cancer Center in 1997 as an Assistant Professor, and was promoted to Associate Professor in 2004. Dr. Winter is currently Professor and Chief of Pediatric Hematology-Oncology at the University of New Mexico Health Science Center. He received his MD from the University of Wisconsin, and then trained in Pediatrics at the University of New Mexico. He then completed a Fellowship in Pediatric Hematology-Oncology at Duke University Medical Center. He joined the faculty of the Department of Pediatrics at the University of New Mexico Health Science Center in 1998. He was appointed the Chief of the Division of Pediatric Hematology-Oncology in 2008, and was awarded the T. John Gribble Endowed Chair in 2009. Both of these clinical investigators play essential roles in the programmatic clinical research of the UNM Cancer Center.
The Clinical Staff Investigators ensure that the Center has experienced clinical faculty in leadership and authorship of clinical trials, to improve accrual of patients on interventional trials, and enhance leadership in cooperative group studies as well as mentoring junior faculty in these areas.
|Flook, Adam M; Yang, Jianquan; Miao, Yubin (2014) Substitution of the Lys linker with the ?-Ala linker dramatically decreased the renal uptake of 99mTc-labeled Arg-X-Asp-conjugated and X-Ala-Asp-conjugated ?-melanocyte stimulating hormone peptides. J Med Chem 57:9010-8|
|Davies, Suzy; Holmes, Anna; Lomo, Lesley et al. (2014) High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer. Int J Gynecol Pathol 33:402-10|
|Wu, Yang; Tapia, Phillip H; Jarvik, Jonathan et al. (2014) Real-time detection of protein trafficking with high-throughput flow cytometry (HTFC) and fluorogen-activating protein (FAP) base biosensor. Curr Protoc Cytom 67:Unit 9.43.|
|Morris, K T; Khan, H; Ahmad, A et al. (2014) G-CSF and G-CSFR are highly expressed in human gastric and colon cancers and promote carcinoma cell proliferation and migration. Br J Cancer 110:1211-20|
|Vaughan, Roger A; Gannon, Nicholas P; Garcia-Smith, Randi et al. (2014) ?-alanine suppresses malignant breast epithelial cell aggressiveness through alterations in metabolism and cellular acidity in vitro. Mol Cancer 13:14|
|Lu, Jie; Hathaway, Helen J; Royce, Melanie E et al. (2014) Introduction of D-phenylalanine enhanced the receptor binding affinities of gonadotropin-releasing hormone peptides. Bioorg Med Chem Lett 24:725-30|
|Campen, Matthew J; Paffett, Michael L; Colombo, E Sage et al. (2014) Muscle RING finger-1 promotes a maladaptive phenotype in chronic hypoxia-induced right ventricular remodeling. PLoS One 9:e97084|
|Yang, Jianquan; Flook, Adam M; Feng, Changjian et al. (2014) Linker modification reduced the renal uptake of technetium-99m-labeled Arg-Ala-Asp-conjugated alpha-melanocyte stimulating hormone peptide. Bioorg Med Chem Lett 24:195-8|
|Hill, Jeff W; Thompson, Jeffrey F; Carter, Mark B et al. (2014) Identification of isoxsuprine hydrochloride as a neuroprotectant in ischemic stroke through cell-based high-throughput screening. PLoS One 9:e96761|
|Scaling, Allison L; Prossnitz, Eric R; Hathaway, Helen J (2014) GPER mediates estrogen-induced signaling and proliferation in human breast epithelial cells and normal and malignant breast. Horm Cancer 5:146-60|
Showing the most recent 10 out of 123 publications